12:00 AM
Mar 05, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Trichuris suis ova: Phase I data

A double-blind, placebo-controlled, U.S. Phase I trial in 36 CD patients showed that single oral doses of 500, 2,500 and 7,500 ova CNDO-201 were well tolerated with no serious adverse events reported at day 14 post-dose. Mild gastrointestinal...

Read the full 167 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >